Paratek Pharmaceuticals, Inc. - FORM 10-Q - EX-32.1 - CERTIFICATION OF THE COMPANY'S CEO AND CFO PURSUANT TO SECTION 906 - November 16, 2009

Attached files

file filename
10-Q - FORM 10-Q - Paratek Pharmaceuticals, Inc.d10q.htm
EX-10.3 - LETTER AGREEMENT - LP CLOVER LIMITED - Paratek Pharmaceuticals, Inc.dex103.htm
EX-10.1 - U.S. LICENSE AND COLLABORATION AGREEMENT - PURDUE PHARMACEUTICAL PRODUCTS L.P. - Paratek Pharmaceuticals, Inc.dex101.htm
EX-31.1 - CERTIFICATION OF THE COMPANY'S CEO PURSUANT TO SECTION 302 - Paratek Pharmaceuticals, Inc.dex311.htm
EX-10.4 - AMENDMENT #2 TO PATHEON MANUFACTURING SERVICES AGREEMENT - Paratek Pharmaceuticals, Inc.dex104.htm
EX-10.5 - AMENDMENT #1 TO SUPPLY AGREEMENT - PIVOT ACQUISITION, INC. AND SPI PHARMA, INC - Paratek Pharmaceuticals, Inc.dex105.htm
EX-10.6 - AMENDMENT #2 TO SUPPLY AGREEMENT - PIVOT ACQUISITION, INC. AND SPI PHARMA, INC - Paratek Pharmaceuticals, Inc.dex106.htm
EX-10.7 - FIRST AMENDMENT PLANTEX SUPPLY AGREEMENT - Paratek Pharmaceuticals, Inc.dex107.htm
EX-31.2 - CERTIFICATION OF THE COMPANY'S CFO PURSUANT TO SECTION 302 - Paratek Pharmaceuticals, Inc.dex312.htm
EX-10.2 - LETTER AGREEMENT - PURDUE PHARMACEUTICAL PRODUCTS L.P. - Paratek Pharmaceuticals, Inc.dex102.htm

Exhibit 32.1

Certification of Chief Executive Officer and Chief Financial Officer

Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

Pursuant to 18 U.S.C. § 1350, as created by Section 906 of the Sarbanes-Oxley Act of 2002, the undersigned officers of Transcept Pharmaceuticals, Inc. (the “Company”) hereby certify, to such officers’ knowledge, that:

(i) the accompanying Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2009 (the “Report”) fully complies with the requirements of Section 13(a) or Section 15(d), as applicable, of the Securities Exchange Act of 1934, as amended; and

(ii) the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

 

Date: November 16, 2009  

/s/ Glenn A. Oclassen

 

Glenn A. Oclassen

President and Chief Executive Officer

Date: November 16, 2009  

/s/ Thomas P. Soloway

 

Thomas P. Soloway

Senior Vice President, Operations and

Chief Financial Officer

Paratek Pharmaceuticals, Inc. Reports